Galane Gold Ltd. (CVE:GG), a junior gold miner, continued to climb after signing a LOI to acquire Vantage Goldfields Limited
Sean Mason | May 24, 2017 | SmallCapPower
A potential acquisition out of Africa propelled shares of a junior gold miner Wednesday. Here’s some small stocks making big moves on Wednesday, May 24, 2017 (as of 4 pm EST):
Galane Gold Ltd. (TSXV: GG) shares continued to move higher Wednesday, up 17% to $0.105. On Tuesday, shares of the junior gold miner surged 29% after it announced that it has signed a letter of intent to acquire all of the outstanding shares of Vantage Goldfields Limited, a gold mining company with operations in the Mpumalanga Province of South Africa.
As well, shares of Oncolytics Biotech Inc. (TSX: ONC) sank 33% to $0.62 as the biotechnology company said it will undertake a public offering of 14.3 million units at a purchase price of $0.70 per unit, for gross proceeds of $10.01 million.
ProMIS Neurosciences (TSX: PMN), meanwhile, reported that it has designated PMN350 – a monoclonal antibody targeting toxic prion-like forms of amyloid-beta oligomers – as the Company’s second lead product for Alzheimer’s disease. ProMIS Neurosciences stock moved up 14% to $0.32 following the announcement.
Finally, Marlin Gold Mining Ltd. (TSXV: MLN) shares rose 10% to $0.79 after the precious metals junior announced drill results from its wholly-owned La Trinidad mine in Mexico, which included 7.57 g/t gold over 63.35 meters.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below:
